CONTRATOS ART. 83
Contrato
Protocol: MS200569_0004. A Phase Ib, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of M5049 Administered Orally in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus Participants Treated with Standard of Care.
Financiador:
IQVIA RDS SPAIN SL
Nacional
date_range
Duración del 26 de junio de 2023 al 26 de junio de 2024
(12 meses)
euro
19.359,12 EUR
De ámbito Nacional.
Investigadores/as
MARIA JULIA
BARBADO AJO
Responsable